Q32 Bio Inc.

NASDAQ:QTTB

Biotechnology

Healthcare
$8.53 -1.70%

-$0.22 today

Market cap
$255.25M
Beta
-0.23
P/E (TTM)
5.4
EPS (TTM)
$2.36
52W Low $1.35High $14.85

Volume 0.26M

Average 0.74M

QTTB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Q32 Bio Inc.NASDAQ: QTTB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.55M rose 15.4% year over year, ahead of the -24.8% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +61.9% a year.

Context

  • Stock-based compensation amounted to 9.8% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.4% holds above the trailing-twelve-month pace of -24.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.55M— QoQ
Last fiscal yearDec 2025
$5.26M+19.8% YoY
LTMMar 2026
$3.99M-24.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.4%——
1 year+19.8%——
3-year CAGR+61.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
5.26M USD
Year-over-year change
+19.8%

Stock-Based Compensation vs competitors

How QTTB compares with its peers on the latest reported figures

  • QTTB's LTM Mar 2026 stock-based compensation of $3.99M is the 4th largest of the 5 companies compared; the peer median is $4.99M.
  • Its year-over-year change of -24.8% is the 2nd highest of 5, against a peer median of -37.5%.
  • Stock-based compensation amounts to 7.4% of revenue for QTTB, versus a peer median of 8.6%.
QTTB Competitors Peer median
Stock-Based Compensation for QTTB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$21.34M +832.2%+24.9%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$5.66M -29.3%+12.5%—
BOLDBoundless Bio, Inc.LTM Mar 2026$4.33M -45.8%+38.8%—
QTTBQ32 Bio Inc.LTM Mar 2026$3.99M -24.8%+61.9%7.4%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$3.19M -47.9%-12.7%8.6%
Peer median (excluding QTTB) $4.99M-37.5%+18.7%8.6%

Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(95.76M)(42.81M)(53.74M)(47.73M)29.82M
Depreciation & Amortization9.54M370K499K487K391K
Deferred Income Tax02.43M000
Stock-Based Compensation01.24M1.43M4.39M5.26M
Change in Working Capital(41.8M)26.94M26.32M(9.64M)(4.04M)
Accounts Receivables00000
Inventory00000
Accounts Payables(2.49M)(1.24M)2.03M(1.04M)(2.11M)
Other Working Capital(39.32M)28.18M24.28M(8.59M)(1.93M)
Other Non-Cash Items18.27M876K6.82M(15.22M)(64.97M)
Operating Cash Flow(109.75M)(10.96M)(18.68M)(67.72M)(33.54M)
Capital Expenditures(2.4M)(2.49M)(5K)(75K)0
Acquisitions (Net)0130M000
Purchases of Investments(97.39M)(157.46M)000
Sales of Investments49M65.46M020M0
Other Investing Activities0(37.98M)007M
Investing Cash Flow(50.79M)(2.47M)(5K)19.93M7M
Debt Repayment030M300K7M(3.13M)
Common Stock Issued52.17M69K106K42M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00046.14M0
Financing Cash Flow52.17M30.07M406K95.14M(3.13M)
Effect of Forex Changes(679K)09.91M00
Net Change in Cash(109.05M)16.65M(8.37M)47.35M(29.67M)
Free Cash Flow(112.15M)(13.44M)(18.68M)(67.79M)(33.54M)

Q32 Bio Inc.

NASDAQ:QTTB

Intrinsic Alpha fair value

Locked

Current Price

$8.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.